Compounds / Longevity / SS-31

SS-31

SS-31 / Elamipretide (Szeto-Schiller Peptide 31)
LongevityFDA ApprovedFDA: FDA ACCELERATED APPROVAL 2025 (Barth...

Overview

Phase II/III heart failure trials. Barth syndrome: FDA accelerated approval 2025. Preclinical: dramatic improvements in mitochondrial function across organ systems.

Mechanism of Action

Selectively targets cardiolipin on inner mitochondrial membrane. Stabilizes electron transport chain complexes. Reduces ROS. Enhances ATP synthesis. Improves mitochondrial cristae structure. FDA accelerated approval 2025 for Barth syndrome.

Pharmacokinetics

Half-life
4 hrs
Peak (Tmax)
30 min
Cleared
~20 hrs

Molecular Profile

Molecular weight
639.8 Da
CAS number
736992-21-5

Key Research Findings

Cardiolipin targeting; mitochondrial protection; FDA accelerated approval 2025 (Barth syndrome); ROS reduction.

Published Research

Br J Pharmacol (2014)
Szeto HH. First-in-class cardiolipin-protective compound as therapeutic agent
View source
JACC (2017)
Saad A et al. Elamipretide (SS-31) in heart failure: Phase II results
View source

Related Longevity Compounds

GHK-CuEpithalonMOTS-cFOXO4-DRINAD+Follistatin 344
Clinical Guidance

Research data is not a treatment plan. If you are considering SS-31, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running SS-31? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals